- Joined
- Feb 12, 2009
- Messages
- 7,550
- Likes
- 1,307
China's Advanced Sciences and Technologies
- Thread starter cir
- Start date
China draws expats from U.S. to launch biotechs
August 19, 2011 — 9:57am ET | By Ryan McBride
With China's government planning to pump hundreds of billions into its biotech sector, the country is motivating scientists from the U.S. and within its own borders to start biotechs.
China is now safely in the U.S. biotech industry's rear view mirror, but the Chinese government reportedly has a 5-year plan to pour more than $300 billion into the country's life sciences sector to to create more than a million biotech jobs. And Chinese expatriates like Duan Peng, a research assistant professor at Rutgers University in New Jersey, are seizing the opportunity to open biotechs in their native country, China Daily reports.
"Although we are comfortable in America, we often felt that something was missing," Ye Xin, who is working with Duan on the start-up, told China Daily. "The missing piece is a sense of achievement. Though we were well paid at the American companies, we wanted to be more than just employees. We are in our mid-30s and wanted to return home and make things happen."
Generous tax policies and government investments in start-ups are propelling new biotech activity in China. With these benefits in mind, Duan and his partners have started a diagnostics company in the city of Nantong in China's Jiangsu province. And more expats like Duan are expected to do the same.
http://www.fiercebiotech.com/story/china-draws-expats-us-launch-biotechs/2011-08-19
China's Biotech Boom – One Person's Answer to Corporate Grief
Friday, 19 August 2011
A couple of Fridays ago, I got a call from an executive who left Big Pharma for less money to join BeiGene, a China-based biotech company. This person described being re-energized as a result of the move. She told me many of her former colleagues are going through the motions at their jobs, waiting for the next big layoff. According to her, many people at her previous employer have lost their enthusiasm for the work and are experiencing "corporate grief." This was a new term for me, so I decided to do some research.
The Five Stages
Apparently, corporate grief is real, and it has the same five stages of death and dying – denial, anger, bargaining, depression, and acceptance. In the case of my friend, acceptance translated into resignation. This seems to be the case for many of the management team members listed on BeiGene's website. John Oyler, CEO and founder of BeiGene, has been grabbing top talent from companies like J&J, GSK, Merck, Lilly, Biogen Idec, BMS, Bayer, and Novartis. Why the sudden interest in jumping ship from billion-dollar blue chips to a small startup in China not yet producing revenue? Because the future of biotech looks bright in China, and the government is willing to back it up with a significant financial investment .
China's Burgeoning Biotech Plan
Reports indicate Chinese officials are willing to put their money where their biotech is, laying out an ambitious plan to generate over a million new biotech jobs before the end of 2015. How? By making biotechnology an economic pillar of Chinese society and funding it with $308 billion. U.S. citizens thought the "Cash for Clunkers" government program designed to stimulate the economy was a big spend at $4 billion — a little over 1% of what China intends to spend on biopharmacy, bioengineering, bio-agriculture, and biomanufacturing. In addition to job creation, the plan intends to extend their people's life expectancies by one year, reduce infant mortality by 12%, and reduce the most common pollutant emissions by 10%. Since 2000, public and private investments in the United States pharma and biotech industries has been nearly a trillion dollars and produced an average of 21 new drugs a year. Will China do better than the United States? My prediction is yes, and here's why.
Why It Will Work
China has the largest standing army in the world with more than 2.3 million members and is not pouring trillions of dollars in military campaigns like the United States is doing in both Afghanistan and Iraq. The 2010 U.S. military budget was $685 billion, compared to China's of $77.9 billion. Acts of terrorism do occur in China. However, China is able to focus most of its military might at a much lower cost to quash these domestic threats. As a result, China can truly focus on economic growth. China has already become the world largest producer of both steel and concrete, so why not drugs? China has a cash surplus and does not have an ingrained way of how to do things in biotechnology. This bodes well for fresh approaches to R&D, with a greater focus on the development component. For a comparable analogy, look back to Japan surpassing the U.S. automobile industry. In my opinion, this bold initiative has the potential to galvanize and unite China, similar to how John F. Kennedy's plan to land an American on the moon did for the United States. According to my friend who made the jump to China' biotech, U.S. companies like Merck (MRK) and Pfizer (PFE) are eager to partner. This is a much different approach than that taken by U.S. automakers with Japan, and as such, provides for the potential of a different outcome for U.S. based biotech. If you can't beat 'em, join 'em.
Life Science Leader - China's Biotech Boom – One Person's Answer to Corporate Grief
August 19, 2011 — 9:57am ET | By Ryan McBride
With China's government planning to pump hundreds of billions into its biotech sector, the country is motivating scientists from the U.S. and within its own borders to start biotechs.
China is now safely in the U.S. biotech industry's rear view mirror, but the Chinese government reportedly has a 5-year plan to pour more than $300 billion into the country's life sciences sector to to create more than a million biotech jobs. And Chinese expatriates like Duan Peng, a research assistant professor at Rutgers University in New Jersey, are seizing the opportunity to open biotechs in their native country, China Daily reports.
"Although we are comfortable in America, we often felt that something was missing," Ye Xin, who is working with Duan on the start-up, told China Daily. "The missing piece is a sense of achievement. Though we were well paid at the American companies, we wanted to be more than just employees. We are in our mid-30s and wanted to return home and make things happen."
Generous tax policies and government investments in start-ups are propelling new biotech activity in China. With these benefits in mind, Duan and his partners have started a diagnostics company in the city of Nantong in China's Jiangsu province. And more expats like Duan are expected to do the same.
http://www.fiercebiotech.com/story/china-draws-expats-us-launch-biotechs/2011-08-19
China's Biotech Boom – One Person's Answer to Corporate Grief
Friday, 19 August 2011
A couple of Fridays ago, I got a call from an executive who left Big Pharma for less money to join BeiGene, a China-based biotech company. This person described being re-energized as a result of the move. She told me many of her former colleagues are going through the motions at their jobs, waiting for the next big layoff. According to her, many people at her previous employer have lost their enthusiasm for the work and are experiencing "corporate grief." This was a new term for me, so I decided to do some research.
The Five Stages
Apparently, corporate grief is real, and it has the same five stages of death and dying – denial, anger, bargaining, depression, and acceptance. In the case of my friend, acceptance translated into resignation. This seems to be the case for many of the management team members listed on BeiGene's website. John Oyler, CEO and founder of BeiGene, has been grabbing top talent from companies like J&J, GSK, Merck, Lilly, Biogen Idec, BMS, Bayer, and Novartis. Why the sudden interest in jumping ship from billion-dollar blue chips to a small startup in China not yet producing revenue? Because the future of biotech looks bright in China, and the government is willing to back it up with a significant financial investment .
China's Burgeoning Biotech Plan
Reports indicate Chinese officials are willing to put their money where their biotech is, laying out an ambitious plan to generate over a million new biotech jobs before the end of 2015. How? By making biotechnology an economic pillar of Chinese society and funding it with $308 billion. U.S. citizens thought the "Cash for Clunkers" government program designed to stimulate the economy was a big spend at $4 billion — a little over 1% of what China intends to spend on biopharmacy, bioengineering, bio-agriculture, and biomanufacturing. In addition to job creation, the plan intends to extend their people's life expectancies by one year, reduce infant mortality by 12%, and reduce the most common pollutant emissions by 10%. Since 2000, public and private investments in the United States pharma and biotech industries has been nearly a trillion dollars and produced an average of 21 new drugs a year. Will China do better than the United States? My prediction is yes, and here's why.
Why It Will Work
China has the largest standing army in the world with more than 2.3 million members and is not pouring trillions of dollars in military campaigns like the United States is doing in both Afghanistan and Iraq. The 2010 U.S. military budget was $685 billion, compared to China's of $77.9 billion. Acts of terrorism do occur in China. However, China is able to focus most of its military might at a much lower cost to quash these domestic threats. As a result, China can truly focus on economic growth. China has already become the world largest producer of both steel and concrete, so why not drugs? China has a cash surplus and does not have an ingrained way of how to do things in biotechnology. This bodes well for fresh approaches to R&D, with a greater focus on the development component. For a comparable analogy, look back to Japan surpassing the U.S. automobile industry. In my opinion, this bold initiative has the potential to galvanize and unite China, similar to how John F. Kennedy's plan to land an American on the moon did for the United States. According to my friend who made the jump to China' biotech, U.S. companies like Merck (MRK) and Pfizer (PFE) are eager to partner. This is a much different approach than that taken by U.S. automakers with Japan, and as such, provides for the potential of a different outcome for U.S. based biotech. If you can't beat 'em, join 'em.
Life Science Leader - China's Biotech Boom – One Person's Answer to Corporate Grief
"Shengli 902", Sinopec's largest pipe-laying vessel built by the Shengli Oilfield Youjian Company, was completed and delivered on 22nd July 2011. This vessel is a multi-functional offshore engineering vessel designed and built completely with the proprietary design and manufacturing technologies. Its functions include laying submarine pipelines and cables, and support for offshore crane operation and construction, etc.
The overall length, width and design displacement of " Shengli 902 Pipelaying Vessel" are, respectively, 118m, 30.4m and 16300t. The vessel is suitable for subsea pipeline operation on max. pipe diameter of 60 inch in 100m-depth water, which operation area may cover continental shelf sea area in China, Indian Ocean and Western Africa Coastal etc., providing Shengli Oil Construction/SINOPEC with mighty support for the development and production of crude oil.
The overall length, width and design displacement of " Shengli 902 Pipelaying Vessel" are, respectively, 118m, 30.4m and 16300t. The vessel is suitable for subsea pipeline operation on max. pipe diameter of 60 inch in 100m-depth water, which operation area may cover continental shelf sea area in China, Indian Ocean and Western Africa Coastal etc., providing Shengli Oil Construction/SINOPEC with mighty support for the development and production of crude oil.
CNOOC to Start Offshore Oil 981 in June
BEIJING, Feb 18, 2011 (SinoCast Daily Business Beat via COMTEX) --
Offshore Oil(Haiyangshiyou) 981 at Shanghai Waigaoqiao Shipbuilding Co., Ltd.
China National Offshore Oil Corp. (CNOOC) is scheduled to drive Offshore Oil 981, or Haiyangshiyou 981 (in Chinese), to South China Sea in June, starting drilling in deep seas for the first time.
The equipment, the world's most advanced 3,000-meter-deep water drilling rig, will leave a shipyard of Shanghai Waigaoqiao Shipbuilding Co., Ltd. under wing of China CSSC Holdings Limited (SHSE: 600150) in two months. It will complete drilling three to four wells within this year.
Offshore Oil 981 will become a major player in exploring and developing China South Sea. The natural gas and petroleum outputs in its deep-water areas will hit 25 million tons of oil equivalents a year in 2015.
In 2020, CNOOC, China's largest offshore oil and gas producer, will strive to reach an annual output of 50 million tons of oil equivalents in these areas in 2020, equal to that of Daqing Oilfield, one of the largest onshore oilfields in the country.
The project is estimated to cost CNY 6 billion. The new deep-water drilling rig is as high as 137 meters and as heavy as more than 30,000 tons.
The drilling rig is filling a gap in China's extra-large equipment manufacturing field targeted at deep-water drilling operation, stressed Fu Chengyu, general manager of CNOOC. Now, the country has reached the sixth generation rig level, the most advanced all over the world. Previously, its semi-submersible rigs were of the world's third generation level.
The new deep-water drilling rig marks the great progress made in offshore drilling technology, pointed out Lin Yaosheng, general manager of the oil and gas giant's deep-water drilling rig engineering project team. It can work at the depth of 3,000 meters at most, compared with 300 meters for current drilling rigs in China.
CNOOC has made great achievements in offshore exploration and exploitation. Slightly earlier, it announced at the end of 2010 that the annual output of the offshore oilfields under its wing surpassed 50 million tons of oil equivalents.
The data suggested that CNOOC, formed in 1982, had reaped oil and gas from offshore assets as much as the output of Shengli Oilfield, the largest onshore oilfield in the country, said industry experts.
In addition, its listed arm CNOOC Limited (SEHK: 0883 and NYSE: CEO | PowerRating) reaped about CNY 38.91 billion un-audited revenues in the third quarter of last year with a surge of 63.8 percent year on year.
The surge was attributed to the increase in oil and natural gas output and oil price rise. It turned out 88.7 million barrels of oil equivalents during the period, rising 48.8 percent from a year earlier.
BEIJING, Feb 18, 2011 (SinoCast Daily Business Beat via COMTEX) --
Offshore Oil(Haiyangshiyou) 981 at Shanghai Waigaoqiao Shipbuilding Co., Ltd.
China National Offshore Oil Corp. (CNOOC) is scheduled to drive Offshore Oil 981, or Haiyangshiyou 981 (in Chinese), to South China Sea in June, starting drilling in deep seas for the first time.
The equipment, the world's most advanced 3,000-meter-deep water drilling rig, will leave a shipyard of Shanghai Waigaoqiao Shipbuilding Co., Ltd. under wing of China CSSC Holdings Limited (SHSE: 600150) in two months. It will complete drilling three to four wells within this year.
Offshore Oil 981 will become a major player in exploring and developing China South Sea. The natural gas and petroleum outputs in its deep-water areas will hit 25 million tons of oil equivalents a year in 2015.
In 2020, CNOOC, China's largest offshore oil and gas producer, will strive to reach an annual output of 50 million tons of oil equivalents in these areas in 2020, equal to that of Daqing Oilfield, one of the largest onshore oilfields in the country.
The project is estimated to cost CNY 6 billion. The new deep-water drilling rig is as high as 137 meters and as heavy as more than 30,000 tons.
The drilling rig is filling a gap in China's extra-large equipment manufacturing field targeted at deep-water drilling operation, stressed Fu Chengyu, general manager of CNOOC. Now, the country has reached the sixth generation rig level, the most advanced all over the world. Previously, its semi-submersible rigs were of the world's third generation level.
The new deep-water drilling rig marks the great progress made in offshore drilling technology, pointed out Lin Yaosheng, general manager of the oil and gas giant's deep-water drilling rig engineering project team. It can work at the depth of 3,000 meters at most, compared with 300 meters for current drilling rigs in China.
CNOOC has made great achievements in offshore exploration and exploitation. Slightly earlier, it announced at the end of 2010 that the annual output of the offshore oilfields under its wing surpassed 50 million tons of oil equivalents.
The data suggested that CNOOC, formed in 1982, had reaped oil and gas from offshore assets as much as the output of Shengli Oilfield, the largest onshore oilfield in the country, said industry experts.
In addition, its listed arm CNOOC Limited (SEHK: 0883 and NYSE: CEO | PowerRating) reaped about CNY 38.91 billion un-audited revenues in the third quarter of last year with a surge of 63.8 percent year on year.
The surge was attributed to the increase in oil and natural gas output and oil price rise. It turned out 88.7 million barrels of oil equivalents during the period, rising 48.8 percent from a year earlier.
High-Quality DNA
In an improbable corner of China, young scientists are rewriting the book on genome research.
by Lone Frank
Newsweek
April 24, 2011
Lab technicians at the Beijing Genomics Institute in Shenzhen, China. Clockwise from upper left: Zhi Wei Luo; Wan Ling Li; Zi Long Zhang; and Yu Zhu Xu.
The world's largest genome-mapping facility is in an unlikely corner of China. Hidden away in a gritty neighborhood in Shenzhen's Yantian district, surrounded by truck-repair shops and scrap yards prowled by chickens, Beijing's most ambitious biomedical project is housed in a former shoe factory.
But the modest gray exterior belies the state-of-the-art research inside. In immaculate, glass-walled and neon-lit rooms resembling intensive care units, rows of identical machines emit a busy hum. The Illumina HiSeq 2000 is a top-of-the-line genome-sequencing machine that carries a price tag of $500,000. There are 128 of them here, flanked by rows of similar high-tech equipment, making it possible for the Beijing Genomics Institute (BGI) to churn out more high quality DNA-sequence data than all U.S. academic facilities put together.
"Genes build the future," announces a poster on the wall, and there is no doubt that China has set its eye on that future. This year, Forbes magazine estimated that the genomics market will reach $100 billion over the next decade, with scientists analyzing vast quantities of data to offer new ways to fight disease, feed the world, and harness microbes for industrial purposes. "The situation in genomics resembles the early days of the Internet," says Harvard geneticist George Church, who advises BGI and a number of American genomics companies. "No one knows what will turn out to be the killer apps." Companies such as Microsoft, Google, IBM, and Intel have already invested in genomics, seeing the field as an extension of their own businesses—data handling and management. "The big realization is that biology has become an information science," says Dr. Yang Huanming, cofounder and president of BGI. "If we accept that [genomics] builds on the digitalization of life, then all kinds of genetic information potentially holds value."
BGI didn't always seem destined for success—or even survival. "The crazy guys" was how Chinese colleagues initially referred to the two founders, Huanming and director Wang Jian. Refused government support, they muscled their way into the international Human Genome Project, mapping out 1 percent of that celebrated first full sequence before tackling the rice-plant genome on their own, beating a well-funded international consortium, and suddenly finding political leverage. Yang and Wang used it to set up the research center, which is nominally nonprofit but carries out commercial activities in support of the research. With an annual grant of $3 million from the local government in exchange for moving to the shoe factory in 2007, BGI first grew modestly, generating income from fee-for-service sequencing and conducting molecular diagnostic tests for hospitals. A $1.5 billion loan from the Chinese Development Bank in 2009 allowed the company to catapult into a different league, and its combination of sequencing power and advanced DNA data-management solutions for the pharma industry are now drawing international attention. Last year, pharmaceutical giant Merck announced plans for a research collaboration with BGI, as the Chinese company's revenue hit $150 million—revenue projected to triple this year. "I admire their passion and the willingness to take risks," says Steven Hsu, a physicist at the University of Oregon, adding that "it permeates the organization."
Others would like to see deeper scientific reflection tempering the monumental ambition. "A more philosophical and conceptual rather than just a technical approach to the genome is needed to foster great discovery," says long-time collaborator Oluf Borbye Pedersen of the University of Copenhagen.
While other well-known genomics centers such as Boston's Broad Institute concentrate more narrowly on human health, the Shenzhen scientists cover a broad biological spectrum. In one shiny lab, thousands of microbes are being scanned for genes that might serve useful industrial purposes, while in another human stem cells are being developed for clinical applications. Scientists have mapped the genomes of everything from cucumbers and 40 different strains of silk worms to the giant panda. They have also cataloged tens of thousands of genes of bacteria living in the human gut, and pieced together the genomic puzzle of an ancient human—an extinct paleo-Eskimo who lived in Greenland 4,500 years ago. While such academic prestige projects are geared toward publication in scientific journals, real-world experimentation is going on at a nearby farm where pigs are cloned to serve as disease models. And in Laos, scientists are testing genetically enhanced plants to feed China's growing population. The institute has already amassed almost 250 potentially lucrative patents covering agricultural, industrial, and medical applications.
Satellite research centers have been set up or are underway in the U.S., Europe, Hong Kong, and four other locations in China, and the number of researchers at the main headquarters in Shenzhen has more than doubled during the past year and a half. The institute now employs almost 4,000 scientists and technicians—and is still expanding.
"I've seen it happen but sometimes even I can't believe how fast we are moving," says Luo Ruibang, a bioinformaticist, who at 23, fits perfectly within the company's core demographic. The average age of the research staff is 26.
Li Yingrui, 24, directs the bioinformatics department and its 1,500 computer scientists. Having dropped out of college because it didn't present enough of an intellectual challenge, he firmly believes in motivating young employees with wide-ranging freedom and responsibility. "They grow with the task and develop faster," he says. One of his researchers is 18-year-old Zhao Bowen. While still in high school, Zhao joined the bioinformatics team for a summer project and blew everyone away with his problem-solving skills. After consulting with his parents, he took a full-time job as a researcher and finished school during his downtime. Fittingly, he now manages a project on the genetic basis of high IQ. His team is sampling 1,000 Chinese adults with an IQ higher than 145, comparing their genomes with those of an equal number of randomly picked control subjects. Zhao acknowledges that such projects linking intelligence with genes may be controversial but "more so elsewhere than in China," he says, adding that several U.S. research groups have contacted him for collaboration. "Everybody is interested in intelligence," he says.
A shoe factory becoming a genomics center, scientists replacing blue-collar workers—the Shenzhen research facility embodies the country's economic and social ambitions. According to a 2010 report from Monitor Group, a management consulting firm based in Boston, China is "poised to become the global leader in life-science discovery and innovation within the next decade."
The Chinese government will, by next year, have spent $124 billion since 2009 building hospitals and health-care centers. Such strategic investments have lured Chinese scientists back to China. So far, at least 80,000 Western-trained Ph.D.s have returned, the vast majority in the past five years. With the country on track to become the second-largest pharmaceuticals market next year, and the U.S. failing behind, afflicted by weak—and declining—government funding of basic science as well as anemic collaboration between private and public sectors, China could take the lead. As George Baeder, vice president of Monitor Group Asia, says, China "has the potential to create a more efficient model for discovering and developing new drugs," a prediction echoed by Caroline Wagner, a science-policy specialist and professor at Pennsylvania State University, who argues in a forthcoming paper that the days of American leadership will soon be gone. "After more than half a century at the top spot, the U.S. will become one big player among several," she says.
But, Wagner adds, "science is not a zero-sum game," and as the pie gets bigger, so will the opportunities for collaboration. Yang, for his part, puts it simply: "Genomics is international," he says. "We must collaborate to survive and develop." Certainly, the scientists at his Shenzhen headquarters have their view on the world. The latest shipment of high-tech toys sits, still unpacked, on the floor; the stamp on the sides of the crates proclaiming: Made in the USA.
Frank is author of the forthcoming book 'My Beautiful Genome.'
http://www.newsweek.com/2011/04/24/h...ality-dna.html
In an improbable corner of China, young scientists are rewriting the book on genome research.
by Lone Frank
Newsweek
April 24, 2011
Lab technicians at the Beijing Genomics Institute in Shenzhen, China. Clockwise from upper left: Zhi Wei Luo; Wan Ling Li; Zi Long Zhang; and Yu Zhu Xu.
The world's largest genome-mapping facility is in an unlikely corner of China. Hidden away in a gritty neighborhood in Shenzhen's Yantian district, surrounded by truck-repair shops and scrap yards prowled by chickens, Beijing's most ambitious biomedical project is housed in a former shoe factory.
But the modest gray exterior belies the state-of-the-art research inside. In immaculate, glass-walled and neon-lit rooms resembling intensive care units, rows of identical machines emit a busy hum. The Illumina HiSeq 2000 is a top-of-the-line genome-sequencing machine that carries a price tag of $500,000. There are 128 of them here, flanked by rows of similar high-tech equipment, making it possible for the Beijing Genomics Institute (BGI) to churn out more high quality DNA-sequence data than all U.S. academic facilities put together.
"Genes build the future," announces a poster on the wall, and there is no doubt that China has set its eye on that future. This year, Forbes magazine estimated that the genomics market will reach $100 billion over the next decade, with scientists analyzing vast quantities of data to offer new ways to fight disease, feed the world, and harness microbes for industrial purposes. "The situation in genomics resembles the early days of the Internet," says Harvard geneticist George Church, who advises BGI and a number of American genomics companies. "No one knows what will turn out to be the killer apps." Companies such as Microsoft, Google, IBM, and Intel have already invested in genomics, seeing the field as an extension of their own businesses—data handling and management. "The big realization is that biology has become an information science," says Dr. Yang Huanming, cofounder and president of BGI. "If we accept that [genomics] builds on the digitalization of life, then all kinds of genetic information potentially holds value."
BGI didn't always seem destined for success—or even survival. "The crazy guys" was how Chinese colleagues initially referred to the two founders, Huanming and director Wang Jian. Refused government support, they muscled their way into the international Human Genome Project, mapping out 1 percent of that celebrated first full sequence before tackling the rice-plant genome on their own, beating a well-funded international consortium, and suddenly finding political leverage. Yang and Wang used it to set up the research center, which is nominally nonprofit but carries out commercial activities in support of the research. With an annual grant of $3 million from the local government in exchange for moving to the shoe factory in 2007, BGI first grew modestly, generating income from fee-for-service sequencing and conducting molecular diagnostic tests for hospitals. A $1.5 billion loan from the Chinese Development Bank in 2009 allowed the company to catapult into a different league, and its combination of sequencing power and advanced DNA data-management solutions for the pharma industry are now drawing international attention. Last year, pharmaceutical giant Merck announced plans for a research collaboration with BGI, as the Chinese company's revenue hit $150 million—revenue projected to triple this year. "I admire their passion and the willingness to take risks," says Steven Hsu, a physicist at the University of Oregon, adding that "it permeates the organization."
Others would like to see deeper scientific reflection tempering the monumental ambition. "A more philosophical and conceptual rather than just a technical approach to the genome is needed to foster great discovery," says long-time collaborator Oluf Borbye Pedersen of the University of Copenhagen.
While other well-known genomics centers such as Boston's Broad Institute concentrate more narrowly on human health, the Shenzhen scientists cover a broad biological spectrum. In one shiny lab, thousands of microbes are being scanned for genes that might serve useful industrial purposes, while in another human stem cells are being developed for clinical applications. Scientists have mapped the genomes of everything from cucumbers and 40 different strains of silk worms to the giant panda. They have also cataloged tens of thousands of genes of bacteria living in the human gut, and pieced together the genomic puzzle of an ancient human—an extinct paleo-Eskimo who lived in Greenland 4,500 years ago. While such academic prestige projects are geared toward publication in scientific journals, real-world experimentation is going on at a nearby farm where pigs are cloned to serve as disease models. And in Laos, scientists are testing genetically enhanced plants to feed China's growing population. The institute has already amassed almost 250 potentially lucrative patents covering agricultural, industrial, and medical applications.
Satellite research centers have been set up or are underway in the U.S., Europe, Hong Kong, and four other locations in China, and the number of researchers at the main headquarters in Shenzhen has more than doubled during the past year and a half. The institute now employs almost 4,000 scientists and technicians—and is still expanding.
"I've seen it happen but sometimes even I can't believe how fast we are moving," says Luo Ruibang, a bioinformaticist, who at 23, fits perfectly within the company's core demographic. The average age of the research staff is 26.
Li Yingrui, 24, directs the bioinformatics department and its 1,500 computer scientists. Having dropped out of college because it didn't present enough of an intellectual challenge, he firmly believes in motivating young employees with wide-ranging freedom and responsibility. "They grow with the task and develop faster," he says. One of his researchers is 18-year-old Zhao Bowen. While still in high school, Zhao joined the bioinformatics team for a summer project and blew everyone away with his problem-solving skills. After consulting with his parents, he took a full-time job as a researcher and finished school during his downtime. Fittingly, he now manages a project on the genetic basis of high IQ. His team is sampling 1,000 Chinese adults with an IQ higher than 145, comparing their genomes with those of an equal number of randomly picked control subjects. Zhao acknowledges that such projects linking intelligence with genes may be controversial but "more so elsewhere than in China," he says, adding that several U.S. research groups have contacted him for collaboration. "Everybody is interested in intelligence," he says.
A shoe factory becoming a genomics center, scientists replacing blue-collar workers—the Shenzhen research facility embodies the country's economic and social ambitions. According to a 2010 report from Monitor Group, a management consulting firm based in Boston, China is "poised to become the global leader in life-science discovery and innovation within the next decade."
The Chinese government will, by next year, have spent $124 billion since 2009 building hospitals and health-care centers. Such strategic investments have lured Chinese scientists back to China. So far, at least 80,000 Western-trained Ph.D.s have returned, the vast majority in the past five years. With the country on track to become the second-largest pharmaceuticals market next year, and the U.S. failing behind, afflicted by weak—and declining—government funding of basic science as well as anemic collaboration between private and public sectors, China could take the lead. As George Baeder, vice president of Monitor Group Asia, says, China "has the potential to create a more efficient model for discovering and developing new drugs," a prediction echoed by Caroline Wagner, a science-policy specialist and professor at Pennsylvania State University, who argues in a forthcoming paper that the days of American leadership will soon be gone. "After more than half a century at the top spot, the U.S. will become one big player among several," she says.
But, Wagner adds, "science is not a zero-sum game," and as the pie gets bigger, so will the opportunities for collaboration. Yang, for his part, puts it simply: "Genomics is international," he says. "We must collaborate to survive and develop." Certainly, the scientists at his Shenzhen headquarters have their view on the world. The latest shipment of high-tech toys sits, still unpacked, on the floor; the stamp on the sides of the crates proclaiming: Made in the USA.
Frank is author of the forthcoming book 'My Beautiful Genome.'
http://www.newsweek.com/2011/04/24/h...ality-dna.html
Last edited:
Walking shovel at China-Eurasia Expo - China.org.cn
Walking shovel at China-Eurasia Expo
Xinhua, September 3, 2011
A gait-model shovel is seen during the ongoing China-Eurasia Expo in Urumqi, northwest China's Xinjiang Uygur Autonomous Region, Sept. 2, 2011. The all-terrain shovel, designed and made by China's leading heavy machinery maker XCMG, is equipped with "walking wheels" which enable it to work under unfavorable circumstances like swamp and steep slope. [Xinhua/Jiang Wenyao]
Walking shovel at China-Eurasia Expo
Xinhua, September 3, 2011
A gait-model shovel is seen during the ongoing China-Eurasia Expo in Urumqi, northwest China's Xinjiang Uygur Autonomous Region, Sept. 2, 2011. The all-terrain shovel, designed and made by China's leading heavy machinery maker XCMG, is equipped with "walking wheels" which enable it to work under unfavorable circumstances like swamp and steep slope. [Xinhua/Jiang Wenyao]
- Joined
- Dec 17, 2009
- Messages
- 13,811
- Likes
- 6,734
China invented a hydraulic backhoe? It is already invented.
BackToEast
Regular Member
- Joined
- Dec 17, 2010
- Messages
- 46
- Likes
- 1
A smart shovel ,a very simple product, why advanced?
China-Tech/Super Capacitor
Tianjin, China - Setp 1, 2011
A new type of energy storage that can supply massive power to electric drive vehicles was created in China Thursday.
Researchers in north China's Tianjin City announced a high-capacity, nickel-carbon supercapacitor (Ni-C supercapacitor) that can hold more energy than a standard capacitor, which is similar to a battery, and can be recharged quickly in 10 minutes for over 50,000 times.
A 10-minute recharge is capable of sustaining 200 kilometers.
The Ni-C super capacitor, which can be widely used in clean-energy vehicles, smart grids, medical apparatuses and aerospace, is also more durable and can be applied in the extremely low temperature between minus 40 degrees Celsius to minus 70 degrees Celsius.
The creation of the super capacitor is expected to be cutting edge of China in the fields of power supply and clean energy based vehicles.
[video]http://newscontent.cctv.com/news.jsp?fileId=116105[/video]
Tianjin, China - Setp 1, 2011
A new type of energy storage that can supply massive power to electric drive vehicles was created in China Thursday.
Researchers in north China's Tianjin City announced a high-capacity, nickel-carbon supercapacitor (Ni-C supercapacitor) that can hold more energy than a standard capacitor, which is similar to a battery, and can be recharged quickly in 10 minutes for over 50,000 times.
A 10-minute recharge is capable of sustaining 200 kilometers.
The Ni-C super capacitor, which can be widely used in clean-energy vehicles, smart grids, medical apparatuses and aerospace, is also more durable and can be applied in the extremely low temperature between minus 40 degrees Celsius to minus 70 degrees Celsius.
The creation of the super capacitor is expected to be cutting edge of China in the fields of power supply and clean energy based vehicles.
[video]http://newscontent.cctv.com/news.jsp?fileId=116105[/video]
Chinese Moon Probe Reaches New Deep Space Destination
SOARING SUCCESS: Technicians assembling Chang'e-II at the Xichang Satellite Launch Centre prior to October 1, 2010 launch. (Photo: Xinhua)
"Diagram of the Lagrange Points associated with the Sun-Earth system (not to scale). Lagrange points are analogous to geostationary orbits in that they allow an object to be in a fixed position in space rather than an orbit in which its relative position changes continuously."
"Chinese Moon Probe Reaches New Deep Space Destination
SPACE.com Staff
Date: 01 September 2011 Time: 04:07 PM ET
Several months after departing from the moon, a Chinese spacecraft has arrived at a new destination about 930,000 miles (1.5 million kilometers) from Earth, according to news reports in China.
The Chang'e 2 moon probe arrived at Lagrange Point 2 (L2) — a place where the gravity of Earth and the sun roughly balance out — on Aug. 25, the Xinhua news service reported Tuesday (Aug. 30). Chang'e 2 had left lunar orbit in early June to head for deeper space.
China is now the world's third nation or agency to put a probe in L2, one of five spots in near-Earth space that serve as a sort of parking lot for spacecraft to hover without being pulled toward any planetary body. NASA and the European Space Agency have also accomplished the feat.
Officials from China's State Administration of Science, Technology and Industry for National Defence (SASTIND) said that Chang'e 2 will carry out exploration activities around L2 over the coming year, Xinhua reported. SASTIND also plans to launch two "measure and control stations" into outer space by the end of 2012, and Chang'e 2 will be used to test the stations' functionality at that time.
Chang'e 2 launched on Oct. 1, 2010, and arrived in lunar orbit five days later. The probe is the second step in China's three-phase moon exploration program, which includes a series of unmanned missions to explore the lunar surface.
This photo, taken by China's Chang'e 2 lunar probe in October 2010, shows a crater in the moon's Bay of Rainbows. The image is one of the first released to the public by China's space agency. (CREDIT: China Lunar Exploration Program)
During its time orbiting the moon, Chang'e 2 took a lot of high-resolution photos to help plan out future missions, which will actually drop hardware onto Earth's nearest neighbor. China is aiming to launch a moon rover around 2012, and another rover will land on the moon and return to Earth with lunar samples around 2017, according to Xinhua.
Chang'e 2 finished up its duties around the moon in April but had enough fuel left over that officials decided to send the probe off into deeper space.
The spacecraft's predecessor, Chang'e 1, launched in October 2007 and conducted a 16-month moon observation mission, after which it crash-landed on the lunar surface by design in March 2009.The Chang'e probes are named after the nation's mythical moon goddess."
SOARING SUCCESS: Technicians assembling Chang'e-II at the Xichang Satellite Launch Centre prior to October 1, 2010 launch. (Photo: Xinhua)
"Diagram of the Lagrange Points associated with the Sun-Earth system (not to scale). Lagrange points are analogous to geostationary orbits in that they allow an object to be in a fixed position in space rather than an orbit in which its relative position changes continuously."
"Chinese Moon Probe Reaches New Deep Space Destination
SPACE.com Staff
Date: 01 September 2011 Time: 04:07 PM ET
Several months after departing from the moon, a Chinese spacecraft has arrived at a new destination about 930,000 miles (1.5 million kilometers) from Earth, according to news reports in China.
The Chang'e 2 moon probe arrived at Lagrange Point 2 (L2) — a place where the gravity of Earth and the sun roughly balance out — on Aug. 25, the Xinhua news service reported Tuesday (Aug. 30). Chang'e 2 had left lunar orbit in early June to head for deeper space.
China is now the world's third nation or agency to put a probe in L2, one of five spots in near-Earth space that serve as a sort of parking lot for spacecraft to hover without being pulled toward any planetary body. NASA and the European Space Agency have also accomplished the feat.
Officials from China's State Administration of Science, Technology and Industry for National Defence (SASTIND) said that Chang'e 2 will carry out exploration activities around L2 over the coming year, Xinhua reported. SASTIND also plans to launch two "measure and control stations" into outer space by the end of 2012, and Chang'e 2 will be used to test the stations' functionality at that time.
Chang'e 2 launched on Oct. 1, 2010, and arrived in lunar orbit five days later. The probe is the second step in China's three-phase moon exploration program, which includes a series of unmanned missions to explore the lunar surface.
This photo, taken by China's Chang'e 2 lunar probe in October 2010, shows a crater in the moon's Bay of Rainbows. The image is one of the first released to the public by China's space agency. (CREDIT: China Lunar Exploration Program)
During its time orbiting the moon, Chang'e 2 took a lot of high-resolution photos to help plan out future missions, which will actually drop hardware onto Earth's nearest neighbor. China is aiming to launch a moon rover around 2012, and another rover will land on the moon and return to Earth with lunar samples around 2017, according to Xinhua.
Chang'e 2 finished up its duties around the moon in April but had enough fuel left over that officials decided to send the probe off into deeper space.
The spacecraft's predecessor, Chang'e 1, launched in October 2007 and conducted a 16-month moon observation mission, after which it crash-landed on the lunar surface by design in March 2009.The Chang'e probes are named after the nation's mythical moon goddess."
"According to an official of TSMC, the company already has 90% of the 28nm foundry market."
Survey reveals mainland China's major chip design companies invest in world-leading 28nm technology
SHENZHEN, China, Sept. 6, 2011 /PRNewswire-Asia/ --
Survey reveals mainland China's major chip design companies invest in world-leading 28nm... -- SHENZHEN, China, Sept. 6, 2011 /PRNewswire-Asia/ --
EE Times-China announces results of its 10th yearly survey on China's fabless semiconductor industry; it also awards the mainland's top IC design houses at annual industry event
SHENZHEN, China, Sept. 6, 2011 /PRNewswire-Asia/ -- Mainland China's leading IC design businesses have adopted cutting-edge 28nm technology to develop chips, while 9.2 percent of local fabless companies are mass producing digital ICs using advanced 45nm or below process technologies, according to the 10th annual IC Design House Survey conducted by EE Times-China, a design engineering title of Global Sources' (NASDAQ: GSOL) joint venture subsidiary, eMedia Asia Limited.
Results of the Survey were announced today at the "2011 IC Design Industry CEO Forum & China IC Design House Awards", with over 150 senior executives from mainland China's IC design industry attending the event. Awards were presented to the Top 10 China Brands, Top 10 Most Promising IC Design Houses, Top 10 Outstanding Technical Support, as well as 25 Hot Products in five categories.
"In the past decade, we have witnessed the emergence and rapid growth of mainland China's IC design industry. When we first started our Survey in 2002, only 20 percent of local IC design firms used 0.25 micrometre or below process technologies, while over 72 percent of their counterparts in the U.S. used 0.18 micrometre or below technologies. Even five years ago, the industry was at least two generations behind the U.S. in terms of process technology," said Brandon Smith, publisher of EE Times-China.
"But this year's Survey indicates that mainland China's leading chip design companies are investing in advanced technologies such as the 28nm designs in order to reduce time-to-market and compete in the global market," Smith added.
Rising use of Taiwan foundries
Survey findings also show that local IC design companies are increasingly using Taiwan foundries to support their high-voltage, high-reliability and high-integration designs. Of those who employ foundry services, 63 percent use foundries based in Taiwan, as compared with 57 percent in 2010. A total of 33.1 percent find Taiwan-based TSMC to be their most suitable foundry partner (30 percent in 2010), while 18.9 percent and 15.0 percent say mainland-based SMIC and CSMC respectively are their best suited foundries.
Mainland China's IC design industry is on a high-growth path. In a recent IHS iSuppli research, operations by fabless semiconductor companies in mainland China are forecasted to generate $10.7 billion in revenue in 2015, more than doubling from $5.2 billion in 2010.
Dr. Wayne Dai, Chairman & CEO of Shanghai-based IC design firm VeriSilicon, said: "The current global environment is very conducive to the rapid development of mainland China's semiconductor companies. The focus of the world's semiconductor industry is increasingly shifting towards mainland China, which accounts for one-third of the global market. Mainland China's share of the world market is expected to continue to increase, and the government's support should help to further promote the industry's development."
Consumer electronics drives industry development
The Survey shows that 57 percent of mainland China's ICs are used for consumer electronics products such as mobile phones and tablet PCs. This market sector is characterized by rapid innovation and intense competition, which is expected to continue to drive the fast development of the local IC design industry.
Currently, 9.2 percent of respondent companies are mass producing digital ICs using 45nm or below process technologies. In the next few years, more major chip design companies in mainland China are expected to successfully develop ICs using advanced 40nm and 28nm process, although 65nm products are expected to be the mainstream in the digital IC segment, according to EE Times-China analysts.
While 23.2 percent and 27.5 percent of respondent companies are using 0.13 micrometre process technologies to make analog and mixed signal ICs, respectively, these two sectors continue to be dominated by 0.18 micrometre and 0.35 micrometre processes.
Other key findings of the Survey:
"¢ The main difficulties when contracting foundries are still costs (59.8 percent) and cycle time (55.9 percent), while inadequate production capacity is less of a problem this year (19.7 percent, as compared with 35 percent in 2010)
"¢ 35.2 percent of respondents get their IP core license from semiconductor foundries, 26.1 percent from design services companies, and 25.4 percent from ARM
"¢ Key challenges respondent companies face during the design process are cost reduction (69.7 percent), low-power design (54.2 percent) and design cycle time (46.5 percent)
Mainland China's top chip design companies and products recognized
The Survey also reveals the top IC design companies in mainland China, as voted by the mainland's systems design engineers. The winners in each category are (in alphabetical order):
"¢ Top 10 China Brands:
Analogix Semiconductor, Fuzhou Rockchip Electronics, Hangzhou Silan Microelectronics, HiSilicon Technologies, Ingenic Semiconductor, RDA Microelectronics, SG Micro, Shanghai AWINIC Technology, Shanghai Fudan Microelectronics and Spreadtrum Communications.
"¢ Top 10 Most Promising China IC Design Houses:
ChipLink Semiconductor, Dioo Microcircuits, Eshine-ic, KT Micro, Leadcore Technology, Panovasic Technology, SENODIA Technologies, Shanghai InfoTM Microelectronics, Shenzhen Chipsea Technologies and Shenzhen Ruichips Semiconductor.
"¢ Top 10 Outstanding Technical Support:
BCD Semiconductor Manufacturing, China Resources Powtech (Shanghai), Hangzhou infix-IP Microelectronics, KrossPower, Shanghai Huahong Integrated Circuit, SINOWEALTH Electronic, SuperPix Micro Technology, VeriSilicon Holdings, Wuxi Si-power Micro-Electronics and Xian Semipower Electronic Technology
EE Times-China analysts have also selected this year's hottest local IC products in five categories:
"¢ Processors: AMLOGIC (AML8726M), HiSilicon Technologies (Hi3516), Montage Technology (Shanghai) (M88CS2000), NUFRONT (NuSmart 2816) and Shanghai InfoTM Microelectronics (IMAPx210)
"¢ Power ICs: KrossPower (AXP173), On-Bright Electronics (Shanghai) (OB2535), Xian Semipower Electronic Technology (SW2604), Shenzhen Ruichips Semiconductor (RU75N08R) and Wuxi Chipown Microelectronics (AP2952)
"¢ Amplifiers/Data converters: GalaxyCore (GC0309), Shanghai Belling (BL6523A), Shenzhen Chipsea Technologies (CS1232), Shenzhen Nsiway Technology (NS4358) and Wuxi Si-power Micro-Electronics (SP9889)
"¢ Controllers/Driver ICs: BCD Semiconductor Manufacturing (AP1681), Dioo Microcircuits (DIO2564), Maxic Technology Corporation (MT7920), Seaward Electronics (SE9120) and Solomon Systech (International) (SSD2533)
"¢ Wireless ICs: Beken Corporation (BK5822), Nationz Technologies (ZM2162), RDA Microelectronics (RDA6231), Simplight Nanoelectronics (SL1300) and Spreadtrum Communications (SC8800G)"
- Joined
- Aug 18, 2011
- Messages
- 90
- Likes
- 10
Anything IndiAN??
Production on major part of China's jumbo rocket completed, maiden voyage before 2015
English.news.cn 2011-09-10 14:34:40 FeedbackPrintRSS
BEIJING, Sept. 10 (Xinhua) -- Production on a major part of China's Long March-5 large-thrust carrier rocket has been completed and its maiden voyage is expected to take place during the country's 12th Five-Year Plan period (2011-2015), according to its producer.
The entire production of the new generations of rockets, including the Long March-5 and -6, will be housed in a large industrial base in north China's Tianjin Municipality, said Ma Xingrui, general manager of the China Aerospace Science and Technology Corporation (CASC), which designs and manufactures major products for the country's space industry such as the Shenzhou manned spacecraft and the Long March rocket series.
The Tianjin Aerospace Industry Base, with an area of 4,700 mu (313.33 hectares), has been built with a total investment of more than 6 billion yuan (938 million U.S. dollars), according to the CASC.
It is designed to meet China's growing demand for space technology research and development over the next 30 to 50 years. By integrating the industrial chain, the base will be able to produce an entire spectrum of rockets of different sizes and types for the nation's moon probe project, space station and other projects, according to the corporation.
The base is built for the design, production, assembly and testing of new generations of carrier rockets, space stations and special equipment, and it provides high-end services such as aerospace software, Ma said.
The construction of a 220,000-sq.m. workshop for new-generation carrier rockets has been completed at the base, he said.
The Long March-5 rocket is scheduled to be put into service in 2014,Liang Xiaohong, deputy head of the CASC-affiliated China Academy of Launch Vehicle Technology which designs and produces the rocket, has said during previous interviews.
With a maximum low Earth-orbit payload capacity of 25 tonnes and high Earth-orbit payload capacity of 14 tonnes, Long March V rockets will be among the world's leaders in payload capacity and reliability, Liang said, adding that the 25-tonne maximum capacity is 2.5 times that of in-service Long March rockets.
The production of a core cabin for China's manned space station and large satellites will also begin during the 2011-2015 period, Ma said.
Production on major part of China's jumbo rocket completed, maiden voyage before 2015
PS work on the LM-7 rocket going well
PSS work on the Wenchang (Hainan Island) Launch Base, China's 4th and the largest, proceeding well, in time for the maiden launch of LM-5 in 2014.
English.news.cn 2011-09-10 14:34:40 FeedbackPrintRSS
BEIJING, Sept. 10 (Xinhua) -- Production on a major part of China's Long March-5 large-thrust carrier rocket has been completed and its maiden voyage is expected to take place during the country's 12th Five-Year Plan period (2011-2015), according to its producer.
The entire production of the new generations of rockets, including the Long March-5 and -6, will be housed in a large industrial base in north China's Tianjin Municipality, said Ma Xingrui, general manager of the China Aerospace Science and Technology Corporation (CASC), which designs and manufactures major products for the country's space industry such as the Shenzhou manned spacecraft and the Long March rocket series.
The Tianjin Aerospace Industry Base, with an area of 4,700 mu (313.33 hectares), has been built with a total investment of more than 6 billion yuan (938 million U.S. dollars), according to the CASC.
It is designed to meet China's growing demand for space technology research and development over the next 30 to 50 years. By integrating the industrial chain, the base will be able to produce an entire spectrum of rockets of different sizes and types for the nation's moon probe project, space station and other projects, according to the corporation.
The base is built for the design, production, assembly and testing of new generations of carrier rockets, space stations and special equipment, and it provides high-end services such as aerospace software, Ma said.
The construction of a 220,000-sq.m. workshop for new-generation carrier rockets has been completed at the base, he said.
The Long March-5 rocket is scheduled to be put into service in 2014,Liang Xiaohong, deputy head of the CASC-affiliated China Academy of Launch Vehicle Technology which designs and produces the rocket, has said during previous interviews.
With a maximum low Earth-orbit payload capacity of 25 tonnes and high Earth-orbit payload capacity of 14 tonnes, Long March V rockets will be among the world's leaders in payload capacity and reliability, Liang said, adding that the 25-tonne maximum capacity is 2.5 times that of in-service Long March rockets.
The production of a core cabin for China's manned space station and large satellites will also begin during the 2011-2015 period, Ma said.
Production on major part of China's jumbo rocket completed, maiden voyage before 2015
PS work on the LM-7 rocket going well
PSS work on the Wenchang (Hainan Island) Launch Base, China's 4th and the largest, proceeding well, in time for the maiden launch of LM-5 in 2014.
- Joined
- Dec 17, 2009
- Messages
- 13,811
- Likes
- 6,734
The title of this thread is an oxymoron.
'America's Nobel' awarded to Chinese scientist
By Elizabeth Weise, USA TODAY
09/12/11
One of medicine's most prestigious prizes this year goes to scientists who discovered how 'machines' within cells control the folding of proteins, a researcher who discovered a new treatment for malaria in ancient Chinese herbal tradition and a health center that has made a specialty of turning scientific advances into innovative therapies.
The Lasker Awards, announced today come with a $250,000 honorarium given each group of researchers. Created in 1945 by the Albert and Mary Lasker Foundation, they are known as "America's Nobels." Many recipients have gone on to receive the Nobel Prize. The awards will be presented on Sept. 23 in New York City.
Basic Medical Research
The Basic Medical Research Award goes to Franz-Ulrich Hartl of the Max Planck Institute of Biochemistry, Germany and Arthur Horwich of Yale University School of Medicine, New Haven, Conn.
Hartl, 54, and Horwich, 60, discovered that proteins cannot fold inside cells by themselves but require another protein, which they call "chaperonin," because it assists in the process. This protein acts as a cage-like folding "machine" that gives the proteins a place to fold away from interference by other cellular activities.
Proteins within cells must fold their amino-acid chains into three-dimensional forms before they can perform their molecular functions within the cell. In the1980s Hartl and Horwich discovered a previously unknown apparatus within the cell encased an unfolded protein, allowing it to take energy from the cell and fold without sticking to other proteins.
Misfolded proteins are a cause of neurodegenerative illnesses such as as Parkinson's, Alzheimer's and amyotrophic lateral sclerosis. The duo's discovery is helping researchers understand how these diseases progress and how they might be treated.
Clinical Research
Tu Youyou of the China Academy of Chinese Medical Sciences, Beijing, receives the Lasker-DeBakey Clinical Medical Research Award for her discovery of the malaria drug artemisinin, which has saved millions from dying from malaria, especially in the developing world.
Tu, 81, began working on malaria during China's Cultural Revolution, when the government launched a secret military project to find a remedy to one of the world's most deadly diseases. Tu went through traditional Chinese medical and folk remedy texts looking for possible treatments. One, the extracts from Artemisia annua L., or sweet wormwood, stopped the parasite's growth. In 1972 they produced a drug that could be used to treat humans.
Public Service
The Clinical Center of the National Institutes of Health in Bethesda, Md. will receive the Lasker-Bloomberg Public Service Award. Since its founding in 1953, Center researchers has targeted diseases ranging from endocrine, neurological, blood, vision, and autoimmune disorders to adrenal problems, vitamin deficiencies, infectious diseases, and behavioral conditions such as schizophrenia and depression as well as AIDS. The Center focuses on understanding basic biological processes so its researchers and physicians can better treat diseases that have eluded diagnosis and treatment.
Tu Youyou, Discoverer Of Malarial Drug, Receives Medical Prize
http://www.huffingtonpost.com/2011/09/12/tu-youyou-malaria-medical-prize_n_958586.html
By Elizabeth Weise, USA TODAY
09/12/11
One of medicine's most prestigious prizes this year goes to scientists who discovered how 'machines' within cells control the folding of proteins, a researcher who discovered a new treatment for malaria in ancient Chinese herbal tradition and a health center that has made a specialty of turning scientific advances into innovative therapies.
The Lasker Awards, announced today come with a $250,000 honorarium given each group of researchers. Created in 1945 by the Albert and Mary Lasker Foundation, they are known as "America's Nobels." Many recipients have gone on to receive the Nobel Prize. The awards will be presented on Sept. 23 in New York City.
Basic Medical Research
The Basic Medical Research Award goes to Franz-Ulrich Hartl of the Max Planck Institute of Biochemistry, Germany and Arthur Horwich of Yale University School of Medicine, New Haven, Conn.
Hartl, 54, and Horwich, 60, discovered that proteins cannot fold inside cells by themselves but require another protein, which they call "chaperonin," because it assists in the process. This protein acts as a cage-like folding "machine" that gives the proteins a place to fold away from interference by other cellular activities.
Proteins within cells must fold their amino-acid chains into three-dimensional forms before they can perform their molecular functions within the cell. In the1980s Hartl and Horwich discovered a previously unknown apparatus within the cell encased an unfolded protein, allowing it to take energy from the cell and fold without sticking to other proteins.
Misfolded proteins are a cause of neurodegenerative illnesses such as as Parkinson's, Alzheimer's and amyotrophic lateral sclerosis. The duo's discovery is helping researchers understand how these diseases progress and how they might be treated.
Clinical Research
Tu Youyou of the China Academy of Chinese Medical Sciences, Beijing, receives the Lasker-DeBakey Clinical Medical Research Award for her discovery of the malaria drug artemisinin, which has saved millions from dying from malaria, especially in the developing world.
Tu, 81, began working on malaria during China's Cultural Revolution, when the government launched a secret military project to find a remedy to one of the world's most deadly diseases. Tu went through traditional Chinese medical and folk remedy texts looking for possible treatments. One, the extracts from Artemisia annua L., or sweet wormwood, stopped the parasite's growth. In 1972 they produced a drug that could be used to treat humans.
Public Service
The Clinical Center of the National Institutes of Health in Bethesda, Md. will receive the Lasker-Bloomberg Public Service Award. Since its founding in 1953, Center researchers has targeted diseases ranging from endocrine, neurological, blood, vision, and autoimmune disorders to adrenal problems, vitamin deficiencies, infectious diseases, and behavioral conditions such as schizophrenia and depression as well as AIDS. The Center focuses on understanding basic biological processes so its researchers and physicians can better treat diseases that have eluded diagnosis and treatment.
Tu Youyou, Discoverer Of Malarial Drug, Receives Medical Prize
http://www.huffingtonpost.com/2011/09/12/tu-youyou-malaria-medical-prize_n_958586.html
Ajeesh Kumar S
Regular Member
- Joined
- Feb 28, 2014
- Messages
- 63
- Likes
- 36
CHINA IS BUILDING ONE OF THE WORLD'S LARGEST SPACE LAUNCH VEHICLES
Long March 5- Prototype In the CALT Tianjin Factory, the first LM-5 rocket takes shape. The diameter of the core, seen here with CALT personnel, is 5 meters. Once operational, the LM-5 will carry up to 25 tons into orbit.
LM-5 Booster-This 3.35 meter wide booster uses a YF-120 liquid oxygen/kerosene engine capable of producing 120 tons of thrust. The LM-5 is planned to carry up to four of these boosters, adding on more boosters would further boost the LM-5's already impressive payload.
http://http://www.popsci.com/long-march-goes?dom=fb&src=SOC
Long March 5- Prototype In the CALT Tianjin Factory, the first LM-5 rocket takes shape. The diameter of the core, seen here with CALT personnel, is 5 meters. Once operational, the LM-5 will carry up to 25 tons into orbit.
LM-5 Booster-This 3.35 meter wide booster uses a YF-120 liquid oxygen/kerosene engine capable of producing 120 tons of thrust. The LM-5 is planned to carry up to four of these boosters, adding on more boosters would further boost the LM-5's already impressive payload.
http://http://www.popsci.com/long-march-goes?dom=fb&src=SOC
Ajeesh Kumar S
Regular Member
- Joined
- Feb 28, 2014
- Messages
- 63
- Likes
- 36
'Human microwave': China's controversial ray gun inflicts unbearable pain
http://http://rt.com/news/214955-china-ray-gun-poly/
http://http://rt.com/news/214955-china-ray-gun-poly/
